

∞ CURRICULUM VITAE ∞

Personal Information:

Sant P. Chawla, M.D., FRACP

Sant P. Chawla M.D., Inc. (Medical Practice)

Sarcoma Oncology Center (Clinical Research Center)

2811 Wilshire Blvd., Suite 414, Santa Monica, CA 90403

Office Phone: (310) 552-9999; Office Fax: (310) 201-6685; Mobile: (310) 500-5391

Email: santchawla@sarcomaoncology.com

Current Positions:

Director, Sarcoma Oncology Center & Sant P. Chawla M.D., Inc.

2811 Wilshire Blvd #414, Santa Monica, CA 90403

Current Appointments and Affiliations:

Stanford University Medical Center , <i>Adjunct Associate Professor</i> Palo Alto, CA	2011-Present
M.D. Anderson Cancer Center , <i>Adjunct Associate Professor</i> University of Texas, Houston, TX	2008-Present
UCLA David Geffen School of Medicine , <i>Assoc. Clinical Professor of Medicine</i> Los Angeles, CA	2004-Present
Cedars-Sinai Comprehensive Cancer Center , <i>Medical Oncologist</i> Los Angeles, CA	1998-Present
USC Keck School of Medicine , <i>Asst. Clinical Professor of Medicine</i> Los Angeles, CA	1998-Present
John Wayne Cancer Institute , <i>Adjunct Faculty, Medical Oncologist</i> Santa Monica, CA	1991-Present

Past Appointments and Affiliations:

Century City Hospital , <i>Director of Medical Oncology</i> 1997-2007 Los Angeles, CA	
Century City Hospital Cancer Center , <i>Associate Director</i> Los Angeles, CA	1999-2005
UCLA-Santa Monica Hospital , <i>Director of Medical Oncology</i> Santa Monica, CA	2004-2008
Orthopaedic Hospital , <i>Director of Medical Oncology</i> Los Angeles, CA	1994-2008

Midway Hospital Cancer Center, *Director of Medical Oncology*
 2004-2005
 Los Angeles, CA

UCLA David Geffen School of Medicine, *Asst. Clinical Professor of Medicine* 1989-2004
 Los Angeles, CA

Hospital of the Good Samaritan, *Director of Developmental Chemotherapy* 1990-1996
 Los Angeles, CA

Comprehensive Cancer Research Group, *Co-Director of Cancer Research* 1990
 Cedars-Sinai Comprehensive Cancer Center

M.D. Anderson Cancer Center
Asst. Professor of Medicine 1986-1988
Melanoma / Sarcoma / Medical Gynecology / Oncology
 University of Texas, Houston, TX

M.D. Anderson Cancer Center, *Asst. Internist* 1986-1988
Department of Medical Oncology
 University of Texas, Houston, TX

Auckland Hospital, *Registrar Clinical Oncology*
 1980-1981
Department of Oncology
 Auckland, New Zealand

Education:

College: University of Rajasthan, *B.S. Premed*
 1970-1971
 Jaipur, India

Medical School: All India Institute of Medical Sciences, *M.B.B.S.* 1971-1975
 New Delhi, India

Rotating Internship: All India Institute of Medical Sciences
 1976
 New Delhi, India

1st Yr Residency: Post Graduate Institute of Medical Sciences, *Internal Medicine* 1977
 Chandigarh, India

2nd-3rd Yr Residency: All India Institute of Medical Sciences, *Internal Medicine* 1977-1980
 New Delhi, India

Registrar: Auckland Hospital, *Medical Oncology*
 1980-1981
 Auckland, New Zealand

Fellowship: M.D. Anderson Cancer Center, *Medical Oncology*

1981-1984
University of Texas, Houston, TX

Fellow Royal Australasian College of Physicians, F.R.A.C.P., Medical Oncology 1980-1981

Licensure

Texas, License No. G-6917 (1984)
California, License No. A45088 (1988)

Board Certifications

American Board of Internal Medicine, 1985 (Valid Indefinitely)
American Board of Medical Oncology, 1987 (Valid Indefinitely)

Teaching Experience

Teach Residents and Students from
UCLA School of Medicine at Orthopaedic Hospital 1992-Present

Teach Fellows, Residents and Students at
Norris Cancer Center, USC Medical Center 1997-Present

Teach Fellows, Residents and Students at
UCLA Medical Center 1988-Present

Teach Fellows, Residents and Students at
Cedars-Sinai Medical Center, Department of Medicine 1988-Present

Taught Fellows, Residents and Students at
M.D. Anderson Cancer Center, Department of Gynecology 1985-1988

Taught House Staff and Students at
Auckland Hospital, New Zealand, Department of Medicine & Medical Oncology 1984-1981

Taught House Staff and Students at
All India Institute of Medical Sciences, Department of Medicine 1978-1979

Society Memberships

- ☒ **American Society of Clinical Oncology (Frequent Presenter)**
- ☒ **American Medical Association**
- ☒ **Los Angeles County Medical Association**
- ☒ **California Medical Association**
- ☒ **Connective Tissue Oncology Society**
- ☒ **Aiimsonians of America (Alumni Association of All India Institute of Medical Sciences)**
- ☒ **Indian Medical Association of Greater Los Angeles (Past President)**

Research Activities

- ☒ **Developmental and Experimental Therapeutics**
- ☒ **Phase I – III Clinical Trials involving Molecular, Biological, Targeted-Gene Therapy and Anti-Neoplastics**
- ☒ **Phase IV Clinical Trials**

☞ PUBLICATIONS & PRESENTATIONS ☛

Peer-Reviewed Publications

1. **Tumor Hypoxia is a Therapeutic Target in Soft Tissue Sarcoma.** *Cancer Discovery*. Published Online First September 11, 2014;doi:10.1158/2159-8290.CD-RW2014-193. Chawla SP, Crammer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE et al.

1. **2. Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activate**
2. **Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft**
3. **Tissue Sarcoma.** *J Clin Oncol* 32 : 2014. Authors: Sant P Chawla, Sarcoma Oncology Center, Santa Monica, CA; Lee D. Cramer, University of Arizona Cancer Center, Tucson, Az; Brian A van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H.Okuno, Mayo Clinic , Rochester, MN; James E. Butrynski, Dana Farber Cancer Institute, Boston, MA; Kristen N. Ganjoo, Stanford University Medical Center, Stanford , CA. Andrew E. Hendifar, Cedars Sinai Hospital , Los Angeles, CA; Stew Kroll, Threshold Pharmaceuticals, South San Francisco;

1. **3. Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).** *J Clin Oncol* 32:5s, 2014. Authors: Isabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litière, Jean-Yves Blay, Axel Le Cesne, Zsuzsanna Papai, Ian Robert Judson, Patrick Schoffski, Sant P. Chawla, Thierry Gil, Sophie Piperno-Neumann, Sandrine Marreaud, Rachel Hodge, Winette T.A. Van Der Graaf; Centre Léon Bérard, Lyon, France; Erasmus MC Cancer Institute, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Gustave Roussy, Villejuif, France; Oncology Department, State Health Center, Budapest, Hungary; The Royal Marsden NHS Foundation Trust, London, United Kingdom;

Laboratory of Experimental Oncology and Department of General Medical Oncology, KU Leuven and University Hospitals, Leuven, Belgium; Sarcoma Oncology Center, Santa Monica, CA; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Institut Curie, Paris, France; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.

4. **Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials.** *J Clin Oncol* 32:5s, 2014. Authors: Keith M. Skubitz, David Morgan Thomas, Sant P. Chawla, Arthur P. Staddon, Jacob Engellau, Amy Feng, Bruce A. Bach; University of Minnesota, Minneapolis, MN; Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Skåne University Hospital, Lund, Sweden; Amgen Inc., Thousand Oaks, CA; Amgen, Inc., Thousand Oaks, CA.
1. **5. Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.** *J Clin Oncol* 32:5s, 2014. Authors: Vivek Narasimhan, James Hu, Kamallesh Kumar Sankhala, Doris V. Quon, Lawrence Menendez, Lita Fernandez, Victoria S Chua, Sant P. Chawla; Sarcoma Oncology Center, Santa Monica, CA; USC Norris Comprehensive Cancer Center, Los Angeles, CA.
2. **6. Randomized phase 2b trial comparing first-line treatment with doxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas.** *J Clin Oncol* 32:5s, 2014. Authors: Sant P. Chawla, Zsuzsanna Papai, Kamallesh Sankhala, Leonid Vasylyev, Guzel Mukhametsina, Mamed Aliev, Kenneth Khamly, Scott Wieland, Daniel J. Levitt; Sarcoma Oncology Center, Santa Monica, CA; Oncology Department, State Health Center, Budapest, Hungary; CTTC Institute for Drug development, San Antonio, TX; Institute of Medical Radiology, Kharkiv, Ukraine; State Healthcare Institute Republican Clinical Oncological Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia; Blokhin Cancer Research Center, Moscow, Russia; Epworth Healthcare and Clinical Trials Research Centre, Richmond, Australia; CytRx Corporation, Los Angeles, CA.
3. **7. 14-day continuous infusion ifosfamide in advanced refractory sarcomas.** *J Clin Oncol* 32:5s, 2014. Authors: Arun S. Singh, Kamallesh Kumar Sankhala, Arnob Mukherjee, Vivek Narasimha, Bartosz Chmielowski, Doris V. Quon, Vicky Chua, Sant P. Chawla; University of California Los Angeles Medical Center, Santa Monica, CA; Sarcoma Oncology Center, Santa Monica, CA; School of Medicine/Translational Oncology Research Laboratory, University of California, Los Angeles, Los Angeles, CA:
4. **8. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.** *Target Oncol.* 2014 May 11. [Epub ahead of print]. Authors: Taberero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J.
5. **9. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study.**

Cancer. 2014 May 2. doi: 10.1002/cncr.28728. [Epub ahead of print]. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ.

6. **10. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.** *Eur J Cancer*. 2014 Apr;50(6):1137-47. doi: 10.1016/j.ejca.2014.01.012. Epub 2014 Feb 7. Authors: Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP.
7. **11 A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.** *Invest New Drugs*. 2014 Feb; 32(1):171-7. doi: 10.1007/s10637-013-0037-6. Epub 2013 Nov 1. Authors: Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Siguero M, Soman N, Chawla SP.
8. **12. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.** *Paediatric Drugs*. 2014 Feb;16(1):21-8. doi: 10.1007/s40272-013-0051-3. Authors: Federman N, Brien EW, Narasimhan V, Dry SM, Sodhi M, Chawla SP.
9. **13. A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.** *Invest New Drugs*. November 01 2013. Authors: Jones, R. L.,Ferrari, S.,Blay, J. Y.,Navid, F.,Lardelli, P.,Alfaro, V.,Siguero, M.,Soman, N. Chawla, Sant.
10. **14. Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets.** *Pediatric Drugs (2013): 1-8 , October 10, 2013*. Authors: Noah Federman, Earl W. Brien, Vivek Narsimhan, Sarah M. Dry, Monish Sodhi, Sant Chawla.
11. **15. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.** *Expert Review of Clinical Pharmacology*,September 2013. Authors: Mita, M. M.,Gong, J, Chawla, Sant.
12. **16. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.** *The Lancet Oncology, Volume 14, Issue 9, Pages 901 - 908, August 2013*. Authors: Sant Chawla, Robert Henshaw, Leanne Seeger, Edwin Choy, Jean-Yves Blay, Stefano Ferrari, Judith Kroep, Robert Grimer, Peter Reichardt, Piotr Rutkowski, Scott Schuetze, Keith Skubitz, Arthur Staddon, David Thomas, Yi Qian, Ira Jacobs.
13. **17 Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.** *Molecular Cancer Therapeutics, February 2013*. Authors: Joseph Tabenero, Sant P. Chawla, Hedy Kindler, Karen Reckamp, E. Gabriela Chiorean, Nilofer S. Azad, A. Craig Lockhart, Cheng-Pang Hsu, Nigel F. Baker, Francesco Galimi, Pedro Beltran, Jose Baselga.
14. **18 Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.** *Cancer Chemotherapy and Pharmacology: Volum 71, Issue 4 (2013), Page 1083-1094*. Authors: Nianhang Chen, Sant P. Chawla, Elena Gabriela Chiorean, William L. Read, Mayer Gorbaty, Alain C. Mita, Lotus Yung, Peter Bryan, Richard McNally,

Markus F. Renschler, Sunil Sharma.

15. **19. Clinical effect of denosumab treatment on giant cell tumor of bone (GCTB).** *Lancet Oncology, February 2013.* Authors: Sant Chawla, Robert Henshaw, Leanne Seeger, Edwin Choy, Jean-Yves Blay, Stefano Ferrar, Judith Kroep, Robert Grimer, Peter Reichardt, Piotr Rutkowski, Scott Schuetze, Keith Skubitz, Arthur Staddon, David Thomas, Yi Qian, Ira Jacobs.
16. **20. Phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.** *BioMed Central, March 2013.* Authors: Sant P. Chawla, Arthur Staddon, Andrew Hendifar, Conrad A. Messam, Rita Patwardhan, Yasser Mostafa Kamel.
17. **21. Moving Beyond Response Criteria: New Measures of Success in the Treatment of Sarcomas.** *Current Treatment Options in Oncology, Online First™, 30 May 2012.* Authors: Andrew E. Hendifar, Elke Ahlmann, Daniel C. Allison, James Hu, Lawrence Menendez, Sant P. Chawla.
18. **22. Seguridad y eficacia de denosumab en el tumor de células gigantes de hueso (TCG): análisis interino de un ensayo de fase 2.** *2º Simposio Nacional de la SEOM, Madrid 24 – 26 Octubre 2012.* Authors: J. Martin Broto (1), J. Y. Blay (2), S. P. Chawla (3), E. Choy (4), M. Dominkus (5), J. Engellau (6), R. Grimer (7), R. M. Henshaw (8), Y. Qian (9), I. A. Jacobs (9).
19. **23. A Meta- Analysis of Osteosarcoma Outcomes in the Modern Medical Era.** *Sarcoma, March, 2012.* Daniel C. Allison, Scott C. Carney, Elke R. Ahlmann, Andrew Hendifar, Sant Chawla, Alex Fedenko, Constance Angeles, and Lawrence R. Menendez.
20. **24. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study.** *Eur J Cancer. 2012 Jan 10.* Authors: Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, Smethurst DP, Bray S, Hei YJ, Blay JY.
21. **25. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.** *J Clin Oncol. 2012 Jan 1;30(1):78-84.* Authors: Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.
22. **26. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.** *J Clin Oncol. 2011 Dec 1;29(34):4541-7.* Authors: Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH.
23. **27. Treatment approaches to sarcoma in the community setting.** *Clin Adv Hematol Oncol. 2011 Jun;9(6):460-1.* Author: Chawla S.P.
24. **28. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.** *Oncology. 2011;80(1-2):50-6* Authors: Ganjoo KN, Cranmer LD,

Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP.

25. 28. **Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery.** *Oncology Reports* (2010) 24, 829-833. Authors: Hall, F.L., Levy J.P., Reed R.A, Petchpud, W.N., Chua V.S., Chawla S.P., Gordon E.M.
26. 30. **Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer.** *Molecular Therapy*, (2010) 18 2, 435–441. doi:10.1038/mt.2009.228. Authors: Chawla S.P., Chua V.S., Fernandez L., Quon D., Blackwelder W.C., Gordon E.M., Hall F.L.
27. 31. **Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules.** Authors: Demetri G.D., Chawla S., et al: *Journal of Clinical Oncology*, Vol 27, No 25 (September 1), 2009: pp. 4188-4196.
28. 32. **Clinical Case Review: Desmoplastic Small Round Cell Tumor: Current Treatment Approach and Role of Targeted Therapy.** *Clin Adv Hematol Oncol.* 2009 Jul;7(7):476-8. Authors: Sankhala, K.K., Chawla S.P.
29. 33. **Perifosine as an active agent in the treatment of patients with advanced sarcoma.** *ASCO-Journal of Clinical Oncology.* Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10059. Authors: Birch R., Chawla S.P., Sarcoma Oncology Center.
30. 34. **Yondelis Sarcoma Study Group. Randomized Phase II study of Trabectedin in patients with Liposarcoma and Leiomyosarcoma after failure of prior anthracyclines (A) and Ifosfamide (I).** *ASCO-Journal of Clinical Oncology.* Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10060. Authors: Morgan J. A., Le Cesne A., Chawla S.P., Mehren M. Von, Schuetze S., Casali P.G., Nieto A., Elsayed Y., Izquierdo M. A. and Demetri G.
31. 35. **Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: Update of phase II trial.** *ASCO-Journal of Clinical Oncology.* Vol 25, No. 18S (June 20, 2007 Supplement), 2007:10076. Authors: Chawla S.P., Tolcher A. W., Staddon A. P., Schuetze S., D’Amato G. Z., Blay J. Y., Loewy J., Kan R. and Demetri G. D., Century City Doctor’s Hospital.
32. 36. **Effects of Denosumab in the treatment of Giant Cell Tumor of Bone: Preliminary results from an open-label phase 2 study.** *CTOS 2007. 2004015 study. Aspire ID 1-V7VJ.* June 18, 2007. Authors: Thomas D., Chawla S.P., Skubitz K., Smith J., Ye Z., Jun S.
33. 37. **AP23573 Sarcoma Phase II Trials, a novel mTOR inhibito, in patients (pts) with advanced soft tissue or bone sarcomas.** *Journal of Clinical Oncology, Vol 24, No. 18S (June 20 Supplement), 2006: 9505.* Authors: Chawla S.P., A.W. Tolcher, A.P. Staddon, S.M. Schuetze, G.Z. D’Amato, J.Y. Blay, K.K. Sankhala, S.T. Daly, V.M. Rivera, G.D. Demetri.
34. 38. **AP23573: A Review of Recent Results, AP23573 is a targeted cancer therapy that inhibits the activity of mTOR, a cellular enzyme that plays a key role in cell growth and proliferation.** *The Liddy Shriver Sarcoma Initiative, Newsletter Vo3 No4,*

<http://www.liddyshiversarcomainitiative.org/Newsletters/V02 N04/AP23573/ap23573.htm>, copyright 2005. Authors: Chawla S.P., Sankhala K. K., Century City Doctors Hospital.

35. **39. Establishing the Dose of MK-0869, an Oral NK1 Antagonist, for the Prevention of Chemotherapy-Induced Nausea and Emesis.** *Cancer* 2003; 97:2290-300. Authors: S.P. Chawla, S.M. Grunberg, R.J. Gralla et al.
36. **40. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High Dose Cisplatin-The Aprepitant Protocol 052 Study Group.** *Journal of Clinical Oncology*, Vol.21, No 22, #4112- 4119, (November 15) 2003. Authors: P.J. Hesketh, S.M. Grunberg, R.J. Gralla, D.G. Warr, F. Roila, R.D. Wit, S.P. Chawla, et.al.
37. **41. Primary chemotherapy for Osteosarcoma with systemic adriamycin and intra-arterial cisplatin.** *Cancer Bulletin*, vol 42:5, 314-317, 1990. Authors: Benjamin R. S., Chawla S.P., Carrasco C.H., Raymond A. K., Murray J. A., and Armen T. O.
38. **42. Osteosarcoma of the Head and Neck.** *Cancer Bulletin*, vol 42:5, 347-354, 1990. Authors: Geopfert H., Raymond A. K., Spires J. R., Chawla S.P., Wolf P. F., Lee Y., and Batsakis, J.G.
39. **43. Osteosarcoma: Angiographic Assessment of Response to Preoperative Chemotherapy.** *Radiology* 170:839-342, 1989. Authors: Carrasco C. H., Claringsangarej C. O., Raymond A. K., Richli W. R., Wallace S., Chawla S.P., Ayala A. G.
40. **44. Recovery of Sperm Production After Chemotherapy for Osteosarcoma.** *Cancer*, 63:2115-2123, 1989. Authors: Meistrick M. L., Chawla S.P., Da Cunha M. F., Johnson S. L., Plager C., Papadopoulos N. E., Lipsultz L. I., Benjamin R. S.
41. **45. Smooth Muscle Neoplasms of the Uterus other than Ordinary Leiomyosarcoma. A Study of 46 cases with Emphasis on Diagnostic Criteria and Prognostic Factors.** *Cancer*, 62:2239-2247, 1988. Authors : Evans H. L., Chawla S.P., Simpson C., Finn K. P.
42. **46. Phase I Study of Weekly-Administered Iproplatin [Cisdichloro-transdihydroxy-bis-isopropylamine platin (chip, JM9)].** *Investigational New Drugs* G:311-317, 1988. Authors: Chawla S.P., Yap B. S., Tenny D. M., Bodey G. P. and Benjamin R. S.
43. **47. Aberrant Oncogene Expression in Uncultured Human Sarcoma and Melanoma.** *Anticancer Research* 7:1117-1124, 1987. Authors: Shin D. M., Gupta V., Ludvik D. , Chawla S.P., Benjamin S., Gutterman J. and Blick M.
44. **48. Clinical Evaluation of Recombinant Interferon alfa-2A (Roferon-A) in Metastatic Melanoma using Two Different Schedules.** *J. Clin Oncol* 5:1240-1246, 1987. Authors: Legha S. S., Papadopoulos N. E. J., Plager C., Ring S., Chawla S.P., Evans L. M., Benjamin R. S.
45. **49. A Randomized trial in Postmenopausal patients with Advanced Breast Cancer Comparing endocrine and Cytotoxic Therapy Given Sequentially or in Combination.** *J. Clin Oncol.* 4:186-193, 1986. Authors: Chawla S.P., (Australian and

New Zealand Breast Cancer Trial Group).

46. **50. Chondro-sarcoma with Additional Mesenchymal component (“de-differentiated Chondrosarcoma) Part I: A Clinicopathological study of 26 cases.** *Cancer* 58:278-286, 1986. Authors: Johnson S., Tetu B., Ayala A. G., and Chawla S.P.
47. **51. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination.** By the Australian and New Zealand Breast Cancer Trial Group, Clinical Oncology Society of Australia. *J. Clin Oncol.* 4:186-193, 1986. Authors: Schwartz M., Chawla S.P., Harvey V., Kay R., Mak D., Manson B., Probert J., Stephens E., Wood H., et al.
48. **52. Phase II Studies of homoharringtone in patients with advanced malignant melanoma; sarcoma; head and neck, breast and colorectal carcinomas.** *Cancer Treatment Reports* 70:375-379, 1986. Authors: Dajani J. A., Dimery I., Chawla S.P., Pinnamaneni K., Benjamin R. S., Legha S. S., and Krakoff I. H.
49. **53. Limb-salvage surgery in osteosarcoma: Early experience at MD Anderson Hospital and Tumor Institute.** *Cancer Treatment Symposia* 3:131-137, 1985. Authors: Murray J. A., Jesspu K., Romsdahl M., Raymond K., Ayala A., Carrasco H., Wallace S., Jaffe N., Benjamin R., Plager C., Papadopoulos N., and Chawla S.P.
50. **54. Evaluation of Novantrone Cardiac Toxicity by Nuclear Angiography and endomyocardial biopsy: An update.** *Proceedings of the Current Status of Novantrone.* Pp 69-73, 1985. Authors: Benjamin R. S., Holmes F., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., Dukart G., and Bodey G. P.
51. **55. Detorubicin - An active anthracycline in untreated metastatic melanoma.** *J. Clin Oncol* 3:1529-1534, 1985. Authors: Chawla S.P., Legha S. S., and Benjamin R. S.
52. **55. Malignant Fibrous Histiocytoma of Jaws: A Clinicopathologic study of eleven cases.** *Cancer* 56:1590-1596, 1985. Authors: Abdul-Karim F. W., Ayala A. G., Chawla S.P., Jing B. S., Geopfert H.
53. **56. Evaluation of Mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update.** *Invest New Drug* 3:117-121, 1985. Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., and Holmes F.
54. **57. Tumor-associated fever in breast cancer.** *Cancer* 53:1596-1599, 1984. Authors: Chawla S.P., Buzdar A., Hortobagyi G., and Blumenschein G.
55. **58. A judicious approach to limb salvage.** *Cancer Bulletin* 36:32-36, 1984. Authors: Benjamin R. S., Murray J. A., Wallace S., Ayala A., Chawla S.P., Raymond A. K., Carrasco C. H., Romsdahl M. M., Papadopoulos N. E. J., and Plager C.
56. **59. High cumulative dose Adriamycin beyond the conventional limits of 500 mg/m² and reduction of cardiotoxicity by continuous infusion schedule** (eds, Spitzky K. H. and Karrer K.). *13th International Congress of Chemotherapy, Vienna, Austria. Verlag H. Egermann, 1983, pp. 546-550.* Authors: Chawla S.P., Benjamin R. S., Ewer M.S., Hortobagyi G. N., Legha S. S., Mackay B., Ali M. K., Carrasco C. H., Wallace S., Haynie III T. P., and Freireich E. J.
57. **60. Role of cardiac biopsy and radionuclide scan in monitoring of adriamycin-**

induced cardiotoxicity, (eds, Spitzky K. H. and Karrer K.). *13th International Congress of Chemotherapy, Vienna, Austria. Verlag H. Egermann, 1983, pp. 490-492.* Authors: Chawla S.P., Benjamin R. S., Legha S. S., Ewer M. S., Ali M. D., Mackay, B., Carrasco C. H., Hortobagyi G. N., Wallace S. Haynie III T. P., and Freireich E. J.

Books and Chapter(s) Publications

- 1. Cisplatin and Adriamycin as Neoadjuvant and Adjuvant Chemotherapy in the management of Soft Tissue Sarcoma.** *Adjuvant therapy of Cancer VI, 1990.* Authors: Chawla S.P., Rosen G., Eilber F., Lowenbraun S., Eckardt J., Morton D. L., Selch M., Greenberg S. And Mirra J.
- 2. Preoperative intra-arterial cisplatin and limb salvage surgery for patients with high grade osteosarcoma of the extremities.** *IN: Adjuvant Therapy of Cancer V. (ed, Salmon S. E.), Grune & Stratton, Florida, 1987, pp 701-710.* Authors: Chawla S.P., Benjamin R. S., Jaffe N., Carrasco C. H., Raymond A. K., Ayala A. G., Wallace S., Armen T., Papadopoulos N. E. J., Plager C., Murray J. A.:
- 3. Adjuvant immunotherapy with Newcastle disease viral oncolysate.** *IN: Adjuvant therapy of Cancer V (ed, Salmon S. E.), Grune & Stratton, Florida, 1987, pp 657-663.* Authors: Plager C., Bowen J. M., Fenoglio C. J., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. D. and Hersh E. M.
- 4. Continuous infusion chemotherapy and concomitant radiation therapy**, (eds, Rosenthal C. J. and Rotman M.). *Plenum Press, New York, 1986, pp 19-25.* Authors: Benjamin R. S., Chawla S.P., Hortobagyi G. N., ewer M. S., Mackay B., Legha S. S., Carrasco C. H., and Wallace S.
- 5. Correlation of ejection fraction and biopsy grades in patients receiving adriamycin.** *IN: Proceedings of the 14th International Congress of Chemotherapy, Kyoto, 1985 (ed, Ishigami J.), University of Tokyo, 1985, pp 251-252.* Authors: Ewer M. S., Chawla S.P., Carrasco C. H., Mackay B., Ali M. K., Haynie III T. P., and Benjamin R. S.
- 6. Adjuvant chemotherapy of primary malignant fibrous histiocytoma of bone: Prolongation of disease-free and overall survival.** *IN: Adjuvant Therapy of Cancer IV (eds, Jones S. E. and Salmon S. E.), Grune & Stratton, Florida, 1984, pp 621-629.* Authors: Chawla S.P., Benjamin R. S., Abdul-Karim F. W., Ayala A. G., Papadopoulos N. E. J., Plager C., Romsdahl M., Jaffe N., Murray J. A.
- 7. Preoperative chemotherapy for osteosarcoma: A treatment approach facilitating limb-salvage wit major prognostic implications.** *IN: Adjuvant Therapy of Cancer IV (eds, Jones S. E. And Salmon S. E.), Grune & Stratton, Florida, 1984, pp 601-610.* Authors: Benjamin R. S., Chawla S.P., Murray J. A., Carrasco C. H., Raymond A. K., Wallace S., Ayala A., Papadopoulos N. E. J., Plager C.
- 8. Mitoxantrone cardiotoxicity: Evaluation by nuclear angiography and endomyocardial biopsy.** *IN: Pharmanual (ed, Smyth J. F.) Sieber & McIntyre, Inc., New Jersey, 1984, pp 49-56.* Authors: Benjamin R. S., Chawla S.P., Carrasco C. H., Mackay b., Haynie T. P., Yap H. V., Blumenschein G. R., Holmes F., Ali M. K., and Bodey G. P.

Abstracts

- 1. Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus**

- doxorubicin in patients with advanced soft tissue sarcomas.** *ASCO Abstract 2014, Abstract # 10502.* Authors: [Sant P. Chawla](#), Zsuzsanna Papai, Kamallesh Sankhala, Leonid Vasylyev, Guzel Mukhametsina, Mamed Aliev, Kenneth Khamly, Scott Wieland, Daniel J. Levitt; Sarcoma Oncology Center, Santa Monica, CA; Oncology Department, State Health Center, Budapest, Hungary; CTRC Institute for Drug development, San Antonio, TX; Institute of Medical Radiology, Kharkiv, Ukraine; State Healthcare Institute Republican Clinical Oncological Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia; Blokhin Cancer Research Center, Moscow, Russia; Epworth Healthcare and Clinical Trials Research Centre, Richmond, Australia; CytRx Corporation, Los Angeles, CA.
- 2. Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).** *ASCO Abstract 2014, Abstract No. 10579.* Authors: Isabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litière, Jean-Yves Blay, Axel Le Cesne, Zsuzsanna Papai, Ian Robert Judson, Patrick Schoffski, [Sant P. Chawla](#), Thierry Gil, Sophie Piperno-Neumann, Sandrine Marreaud, Rachel Hodge, Winette T.A. Van Der Graaf; Centre Léon Bérard, Lyon, France; Erasmus MC Cancer Institute, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Gustave Roussy, Villejuif, France; Oncology Department, State Health Center, Budapest, Hungary; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Laboratory of Experimental Oncology and Department of General Medical Oncology, KU Leuven and University Hospitals, Leuven, Belgium; Sarcoma Oncology Center, Santa Monica, CA; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Institut Curie, Paris, France; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
- 3. Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials.** *ASCO Abstract 2014, Abstract No. 10505.* Authors: Keith M. Skubitz, David Morgan Thomas, [Sant P. Chawla](#), Arthur P. Staddon, Jacob Engellau, Amy Feng, Bruce A. Bach; University of Minnesota, Minneapolis, MN; Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Skåne University Hospital, Lund, Sweden; Amgen Inc., Thousand Oaks, CA; Amgen, Inc., Thousand Oaks, CA.
- 4. Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.** *ASCO Abstract 2014, Abstract No. 10599.* Authors: Vivek Narasimhan, James Hu, Kamallesh Kumar Sankhala, Doris V. Quon, Lawrence Menendez, Lita Fernandez, Victoria S Chua, [Sant P. Chawla](#); Sarcoma Oncology Center, Santa Monica, CA; USC Norris Comprehensive Cancer Center, Los Angeles, CA.
- 5. 14-day continuous infusion ifosfamide in advanced refractory sarcomas.** *ASCO Abstract 2014, Abstract No. 10596.* Authors: Arun S. Singh, Kamallesh Kumar Sankhala, Arnob Mukherjee, Vivek Narasimha, Bartosz Chmielowski, Doris V. Quon, Vicky Chua, [Sant P. Chawla](#); University of California Los Angeles Medical Center, Santa Monica, CA; Sarcoma Oncology Center, Santa Monica, CA; School of Medicine/Translational Oncology Research Laboratory, University of California, Los Angeles, Los Angeles, CA.

6. **Efficacy and safety of denosumab in giant cell tumor of bone.** *GCTB encore submission to ISOLS*. Authors: Robert Grimer, Jean-Yves Blay, Sant P. Chawla, Edwin Choy, Stefano Ferrari, Peter Reichart, Piotr Rutkowski, David Thomas, Yi Qian, Ira Jacobs.
7. **Phase 1b study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma.** *(ASTS) ASCO 2013*. Authors: SP Chawla, JY Blay, A Italiano, M Gutierrez, A Le Cesne, CA Gomez-Roca, L Gouw, M von Mehren, AJ Wagner, RG Maki, BX Higgins, S Middleton, G Nichols, D Geho, S Blotner, J Zhi, LC Chen.
8. **Seguridad y eficacia de denosumab en el tumor de células gigantes de hueso (TCG): análisis interino de un ensayo de fase 2.** *Submitted 2º Simposio Nacional de la SEOM, Madrid 24 – 26 Octubre 2012*. Authors: J. Martin Broto (1), J. Y. Blay (2), S. P. Chawla (3), E. Choy (4), M. Dominkus (5), J. Engellau (6), R. Grimer (7), R. M. Henshaw (8), Y. Qian (9), I. A. Jacobs (9).
9. **Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy.** *Submitted to 2012 ASCO Annual Meeting, June 1-5, 2012*. Authors: Nicolas Penel, George D. Demetri, Jean-Yves Blay, Sophie Cousin, Robert G. Maki, Sant P. Chawla, Ian Robert Judson, Margaret von Mehren, Patrick Schoffski, Jaap Verweij, Paolo Giovanni Casali, Sjoerd Rodenhuis, Javier Gomez, Antonio Nieto, Patrik Zintl, Maria Jose Pontes Valero, Alexia Cassar, Axel Le Cesne; Centre Oscar Lambret, Lille, France; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; University Claude Bernard Lyon I, Centre Léon Bérard, Lyon, France; Mount Sinai School of Medicine, New York, NY; Sarcoma Oncology Center, Santa Monica, CA; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Fox Chase Cancer Center, Philadelphia, PA; Department of General Medical Oncology, Leuven Cancer Institute, Catholic University of Leuven, Leuven, Belgium; Erasmus University Medical Center, Rotterdam, Netherlands; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam.
10. **Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity.** *J Clin Oncol 30, 2012 (suppl; abstr 3015); ASCO 2012*. Authors: Andrew Eugene Hendifar, Sant P. Chawla, Doris Quon, Victoria S Chua, Lita Fernandez, Sandeep Nagre, Marita Okunnu, Bartosz Chmielowski, Arun S. Singh, Slava Akmaev, David Chatman, John McCook, Shen Luan, Rangaprasad Sarangarajan, Paul Y. Song, Niven R Narain.
11. **Phase Ib/II study of INNO-206 (EMCH-doxorubicin) in patients with soft tissue sarcoma.** *J Clin Oncol 30, 2012 (suppl; abstr 10036); ASCO 2012*. Authors: Sant P. Chawla, Victoria S Chua, Andrew Hendifar, Doris Quon, Sandeep Nagre, Kristen N. Ganjoo, Kamallesh Sankhala, Scott Wieland, Daniel Levitt.
12. **Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant Cell Tumor of Bone.** *Submitted to Clinical Cancer Research February, 2012*. Authors: Daniel G. Branstetter, Scott D. Nelson, J. Carlos Manivel, Jean-Yves Blay, Sant Chawla, David M. Thomas, Susie Jun, Ira Jacobs.
13. **Evaluating the Safety and Efficacy of Denosumab in Patients with Giant Cell Tumor of Bone (GCTB): Second Interim analysis from A Phase 2 Study.** *Submitted to 2011*

CIBD Conference Nov 30- Dec 3, 2011. Authors: Chawla S., et al.

14. **Denosumab Safety and Efficacy in Giant Cell Tumor of Bone (GCTB): Interim Results From A Phase 2 Study.** *2011 ASCO Annual Meeting, June 3-7, 2011. Abstract #82649.* Authors: Chawla S., et al.
15. **The GeneVieve Protocol.** *2011 ASCO Annual Meeting, June 3-7, 2011. Abstract #49252.* Authors: Ignacio J.G., Chawla S.P., et al: A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy.
16. **A Randomized Multicenter Phase III Trial of Trabectedin (T) vs Doxorubicin-Based Chemotherapy (DXCT) as First-Line Therapy (Rx) in Patients (pts) with Translocation Related Sarcoma (TRS).** *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Chawla S.P., et al.
17. **A Phase 3, randomized, placebo-control trial evaluating the mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients who achieve clinical benefit from chemotherapy (SUCCEED trial).** *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Chawla S.P., et al.
18. **PALETTE: A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma (STS) whose disease has progressed during or following prior therapy. An EORTC STBSG global network study (EORTC 62072).** *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Van der Graaf WTA, Blay JY, Chawla S., et al.
19. **A Phase 2 Dose Expansion of TH-302 in Combination with Doxorubicin in Soft Tissue Sarcoma.** *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Ganjoo K.N., Cranmer L., Adkins D., Reed D.R., Okuno S.H., Butrynski J.E., Rushing D., Lorente G.A., Kroll S., Chawla S.P.
20. **A Phase I study to assess pharmacokinetics, QT/QTc effect, and safety of amrubicin in patients with advanced solid tumors.** *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Sharma S., Chawla S., et al.
21. **A Phase II Study of VEGF-antisense compound (VEGF-AS, Veglin) with Pemetrexed and Cisplatin in Patients with Malignant Mesothelioma.** *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Chawla, S.P., et al.
22. **A Phase II Study of VEGF-AS Veglin With Pemetrexed and Cisplatin, CAV Regimen, in the Treatment of Patients With Malignant Mesothelioma.** *2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, December 9-11, 2010. Abstract #161.* Authors: Chawla S.P., Lazaro C.B., Hendifar A., Gupta R.R., Rana R., Nadadur R. Chua V.S.
23. **A Phase II Study of Low Dose TAG (Taxotere, Adriamycin, Gemcitabine) as Salvage Therapy for Soft Tissue Sarcoma.** *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #896893.* Authors: Ganjoo K.N., Jahan T.M., Lazaro C.B., Chen A.L., Gupta R.R., Jain R.K., Chua V.S., Cranmer L.D., Chawla S.P.
24. **A Phase ½ Study of TH-302 in Combination with Doxorubicin in Soft Tissue Sarcoma.** *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900676.* Authors:

Chawla, S.P., et al.

25. **Efficacy and Safety of Conatumumab Plus AMG 479 in Patients (PTS) with Advanced Sarcoma.** *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #890126.* Authors : Chawla S.P., et al.
26. **Yondelis® (Trabectedin) hepatic safety profile as single-agent in soft tissue sarcoma (STS): Pooled analysis of phase II trials.** *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #876470.* Authors: Demetri G.D., Le Cesne A., Yovine A., Maki R., Chawla S.P., et al.
27. **A Phase II trial of R1507, a monoclonal antibody to the Insulin-Like Growth Factor-1 receptor (IGF1R) in patients with recurrent or refractory bone and soft tissue sarcomas excluding ESFT.** *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900715.* Authors: Pappo A., Patel S., Crowley J., Reinke D., Brownstein C., Chawla S., et al.
28. **Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma.** *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #890419.* Authors: Ganjoo K.N., Chawla S.P., et al.
29. **Denosumab in Giant Cell Tumor of Bone: Interim Results from a Phase 2 Study.** *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900789.* Authors: Chawla S.P., et al.
30. **Denosumab decreases proliferation in Giant Cell Tumor of Bone (GCTB).** *10th International Conference on Cancer-Induced Bone Disease. Sept 22 – Sept 25, 2010.* Authors: Roudier M., Blay J.Y., Chawla S., et al.
31. **Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Infusions of Retrovector Encoding Mutant Anti-Cyclin G1 as Stand-alone Therapy for Chemotherapy-Resistant Bone and Soft Tissue Sarcoma.** *2010 ASCO Abstract. June 4 - June 8, 2010. Abstract #: 10010.* Authors: Ganjoo K.N., Chawla S.P., et al.
32. **A phase I/II study of intravenous rexin-g and reximmune-c for cancer immunotherapy: The GeneVieve protocol.** *2010 ASCO Abstract. June 4 - June 8, 2010. Abstract #: 49252.* Authors: Ignacio J.G., Chawla S.P., et al.
33. **An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide;** *2010 ASCO Abstract. June 4 - June 8, 2010.* Authors: Chawla S.P., Staddon A.P., Messam C., Graham A.M., Mostafa Kamel Y.M.
34. **Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.** *2010 ASCO Abstract. June 4 - June 8, 2010.* Authors: Chawla S.P., Taberero J., Kindler H.L., Chiorean E.G., LoRusso P., Hsu M., Haddad V., Bach B.A., Baselga J.
35. **TH-302, a novel tumor-selective hypoxia-activated prodrug (HAP): Phase 1 safety and activity as monotherapy and in combination with gemcitabine, docetaxel, pemetrexed and doxorubicin.** *2010 New Zealand Society for Oncology Annual*

Conference Abstract. Authors: Langmuir V, Kroll S, Weiss G, Infante J, Borad M, Chiorean E G, Mita A, Ganjoo K, Chawla S, et al.

36. **Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): results of a pooled analysis of five single-agent phase II studies.** *2010 ASCO Abstract. June 4 - June 8, 2010.* Authors: Judson I, Blay J Y, Chawla S, Radford J, Le Cesne A, Verweij J, VonMehren M, Demetri G.
37. **Targeting tumor hypoxia with TH-302: Phase I results with monotherapy and combination with chemotherapy.** Authors: Chawla SP, et al.
38. **Evaluation of the Safety and Efficacy of "Pathotropic" Nanoparticles Bearing a Dominant-Negative Cyclin G1 Construct (Rexin-G) as Monotherapy for Chemo-Resistant Osteosarcoma and Other Sarcomas -- Phase I/II and Phase II Studies;** *2009 ASCO Annual Meeting. May 30, 2009. Abstract #10513. J Clin Oncol 27:15s, 2009.* Authors: Chawla S.P., Chua V.S., Fernandez L., Quon D., Saralou A., Blackwelder W.C., Hall F.L., Gordon E.M.
39. **Denosumab for the Treatment of Giant Cell Tumor (GCT) of Bone: Final results from a Proof-of-Concept, Phase 2 Study.** 2004015 study. *2009 ASCO Annual Meeting. May 30-June 1, 2009. Abstract #10510. J Clin Oncol 27:15s, 2009.* Authors : Thomas D., Chawla S.P., et al.
40. **Phase I/II Study of TH-302 Combined with Doxorubicin in Soft Tissue Sarcoma (STS): Preliminary Results.** *Submitted CTOS 2009.* Authors: K.N. Ganjoo, L.D. Cranmer, S. Kroll, V.K. Langmuir, S.P. Chawla.
41. **Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin (mTOR) in cancer patients.** *Cancer. Submitted February 25, 2009.* Authors: Sonis S., Treister N., Chawla S.P., Demetri G., Haluska F.
42. **A study of Palifosfamide in Combination with Doxorubicin: Safety and Preliminary Efficacy;** CTOS 2008. IPM 1002 Study. *November 13-15, 2008. Abstract # 35011.* Authors: S.P. Chawla, L. Camacho, V.S. Chua, G. Abbadessa, B. Schwarz.
43. **Phase I/II Study of Targeted Gene Delivery In Vivo – Intravenous Infusion of Pathotropic Nanoparticles bearing a Cytocidal Cyclin G1 Construct (Rexin-G) – Demonstrates Anti-Tumor Activity in Chemo-Resistant Metastatic Bone and Soft Tissue Sarcoma.** *CTOS 2008. C07-103, C07-110 Study. November 13-15, 2008. Abstract # 34963.* Authors: V.S. Chua, S.P. Chawla, A. Kalra, D. Quon, K. Beltran, A Saralou, K.Y. Kita, E.M. Gordon, F.L. Hall.
44. **Phase II Study of Pathotropic Nanoparticles Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) Reveals Significant Anti-Tumor Activity with No Toxicity in Chemo-Resistant Metastatic Osteosarcoma;** CTOS 2008. C07-110 Study. *November 13-15, 2008. Abstract # 34960.* Authors: S.P. Chawla, V.S. Chua, A. Kalra, D. Quon, K. Beltran, A. Saralou, K.Y. Kita, F.L. Hall, E.M. Gordon.
45. **A Phase 1b Open-label Study of AMG 655 in Combination with Doxorubicin for the First-line Treatment of Patients with Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma;** CTOS 2008. 20060324 study. *November 13-15, 2008. Abstract # 34845.* Authors: J.Y. Blay, S Chawla, et al.

46. **Initial Results of a Phase II Study of the Safety and Efficacy of the Apomab DR5 Agonist Antibody in Advanced Chondrosarcoma and Synovial Sarcoma Patients;** CTOS 2008. APM 4171G Study. *November 12-15, 2008. Abstract # 35010.* Authors: S Chawla, et al.
47. **Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute.** *Proceedings of ASCO 2008, Volume 26, Abstract # 21506.* Authors: V. Mohan, T. Chawla, K. Alzawahereh, W. Jeong, K.Y.Kita, V.S. Chua, A. Kalra, G.S. Rana, S.P. Chawla.
48. **Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma.** *Proceedings of ASCO 2008, Volume 26, Abstract # 16024.* Authors: M. T. Schreeder, R.A. Figlin, J.J. Stephenson, L. Campos, S.P. Chawla, D.R. Spigel, A. Spira, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson.
49. **Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC).** *Proceedings of ASCO 2008, Volume 26, Abstract # 14565.* Authors: J.P. Allerton, B. Ebrahimi, M. T. Schreeder, P. Kaiser, S.P. Chawla, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson.
50. **Phase I/II study of targeted gene delivery in vivo – intravenous infusions of Regin-G – demonstrate significant biologic activity by FDG PET-CT without toxicity in patients with progressive chemo-resistant sarcoma, breast cancer, and pancreatic cancer.** *Proceedings of ASCO 2008, Volume 26, Abstract # 14509.* Authors: S.P. Chawla, V.S. Chua, V. Mohan, K. Alzawahereh, A. Kalra, D. Quon, E.M. Gordon, F.L. Hall.
51. **Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study.** *Proceedings of ASCO 2008, Volume 26, Abstract # 10500.* Authors: D. Thomas, S.P. Chawla, K. Skubitz, A.P. Staddon, R. Henshaw, J.Y. Blay, J. Smith, Z. Ye, M. Roudier, S. Jun.
52. **Assessing the Clinical Impact of Trabectedin in Patients with Leiomyosarcoma or Liposarcoma (L- sarcomas) Progressing Despite Prior Conventional Chemotherapy: Clinical Benefit Rate, Growth Modulation Index and Tumor Variation as Parameters of Treatment Effect in a Randomized International Trial of Two Trabectedin Dosing Regimens.** *ASCO-Journal of Clinical Oncology. Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10060.* Authors: Cesne A. L., Mehren M. V., Chawla S.P., et al.
53. **Post-Ifosfamide therapy inflammation in musculoskeletal and soft-tissue sarcomas: Evaluation with F-18 FDG PET and PET/CT.** *Proceedings of 2006 SNM 53rd Annual Meeting, Pub. No. 1358, Ref. # 222045.* Authors: Lagaru, R. Masamed, K.K. Sankhala, S.P. Chawla, L. Menendez, A. Fedenko and P.S. Conti, et al.
54. **CHOP and Radiation: An Effective Therapy for Primary Lymphoma of the Bone.** *Proceedings of ASCO, 2003; Abstract # 2487.* Authors: S.P. Chawla, E.W. Brien, R. Bhuva, L. Menendez, et, al.
55. **Aprepitant 052 and 054 Study Groups.** *Proceedings of ASCO 2003, Volume 22, Abstract # 2919.* Authors: D. Warr, R.J. Gralla, P.J. Hesketh, S.P. Chawla, et al.
56. **Newer Antiemetic and NK Inhibitor.** *Proceedings of American Society of Clinical*

Oncology, Vol. 20, Abstract #1527, 2001. Authors: S. Chawla, et al.

- 57. Successful Treatment of Multiple Myeloma Relapsed After High Dose Chemotherapy With Non-Myeloablative Stem Cell Transplant.** UCLA Medical Center, Los Angeles, CA. *American Society of Clinical Oncology Official Abstract #144, 1999.* Authors: C. Emmanouilides, B. Vescio, S. Chawla, J. Berenson, M. Territo, G. Schiller.
- 58. Systemic Irinotecan (CPT-11) and Regional Chemotherapy Prolong Survival After Hepatic Cryosurgery in Patients With Metastatic Colon Cancer Refractory to 5-Fluorouracil (5-FU).** John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA and Century City Hospital, Los Angeles, CA. *American Society of Clinical Oncology Official Abstract #975, 1999.* Authors: J. Bilchik, S. Chawla, D. M. Rose, S. Stern, K. P. Ramming.
- 59. Role of Alfa-Interferon in Reducing Risk of Metastasis in Patients With Poor Prognosis Osteosarcoma.** Orthopedic Hospital, Los Angeles, CA, UCLA School of Medicine, Los Angeles, CA, USC School of Medicine, Los Angeles, CA and Century City Hospital, Los Angeles, CA. *1999 Annual Meeting of the American Society of Clinical Oncology, Abstract #151092.* Authors: S.P. Chawla, V. S. Chua, P. Bauer, T. Ganim, L. Menendez, E. Brien, J. Eckardt and F. Eilber.
- 60. Cryosurgical Ablation of Soft Tissue Sarcomas: A Phase 1 Study of Feasibility and Safety.** *9th International Society of Limb Salvage, September 10-12, 1997, New York, New York.* Authors: L. R. Menendez, Matthew Tan, Milton Kiyabu and Sant P. Chawla.
- 61. A Multiple Marker RT-PCR Assay for Detection of Occult Metastasis in Frozen Sections of Sentinel Nodes from Breast Cancer Patients.** Joyce Eisenberg Keefer Breast Center, Santa Monica, CA and the National Genetics Institute, Los Angeles, CA. *Proceedings of American Society of Clinical Oncology, Vol. 16, 536, 1997.* Authors: P. Bostick, T. Sarantou, K. Huynh, A. Conrad, S.P. Chawla, A. Guiliano and D. Hoon.
- 62. Efficacy and Safety of Oral Granisetron versus IV Ondansetron in Prevention of Moderately Emetogenic Chemotherapy-induced Nausea and Vomiting.** Mayo Clinic, Jacksonville, FL, UCLA School of Medicine, Santa Monica, CA, Oncology and Hematology Group of South Florida, Miami, FL; Smith Kline Beecham Pharmaceuticals, Collegeville, PA. *Proceedings of ASCO, Vol. 16, 149, 1997.* Authors: E. Perez, S.P. Chawla, P. K. Kaywin, etc.
- 63. The Value of Ifosfamide in Postoperative Neoadjuvant Chemotherapy of Osteosarcoma.** *Proceedings of American Society of Clinical Oncology, vol 14, pp 516, #1690, 1995.* Authors: Benjamin R. S., Patel S. R., Armen T., Carrasco C. H., Raymond A. K., Ayala a. G., Chawla S.P., Yasko A. W. and Murray J.
- 64. Chemosensitivity for Malignant Melanoma Correlated With Clinical Response: Identification of a Subgroup of Patients Unlikely to Respond to Chemotherapy.** John Wayne Cancer Institute, Saint John's Hospital and Health Center, Santa Monica, CA 90404. *Proceedings of American Society of Clinical Oncology, vol 13, pp 398, #1358, 1994.* Authors: Barth A., Cabot M., Chawla S.P., Boasberg P., Foshag L., Gotis J. and Morton D. L.
- 65. Response to Chemotherapy in Melanoma Patients After Active Specific Immunotherapy (ASI) with Melanoma Cell Vaccine (MCV).** John Wayne Cancer

Institute, Saint John's Hospital and Health Center, Santa Monica, CA 90404.
Proceedings of American Society of Clinical Oncology, vol 12, pp 396, #1355, 1993.
Authors: Foshag L. J., Morton D. L., Nizze J. A. and Chawla S.P.

66. **Primary Chemotherapy of Osteosarcoma of the Extremities - Long Term Follow-up.** *Proceedings of American Society of Clinical Oncology, vol 12, pp 470, #1639, 1993.*
Authors: Benjamin R. S., Patel S. R., Armen T., Carrasco C. H., Raymond A. K., Ayala A. G., Chawla S.P. and Murray J.
67. **High Dose Ifosfamide therapy in Metastatic Soft Tissue Sarcoma.** *Proceedings American Association for Cancer Research, vol 30, 1990.* Authors: Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.
68. **Role of Adriamycin and Cisplatin in therapy of Soft Tissue Sarcomas.** *6th International Conference of Adjuvant therapy of Cancer, March 7-11. Tucson, Arizona, 1990.* Authors: Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.
69. **Role of High Dose Ifosfamide in Recurrent Osteosarcoma.** *Proceedings of American Society of Clinical Oncology, #1210, vol 9, pp 310, 1990.* Authors: Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.
70. **Phase II Study of High Dose Continuous Infusion of Dimethyl Traizeno Imidazole Carboxamide (DTIC) in Metastatic Leiomyosarcoma.** *Proceedings American Society of Clinical Oncology, #1210, vol 9, pp 313, 1990.* Authors: Rosen G., Chawla S.P., Hamburg S. and Lowenbraun S.
71. **Effects of Recombinant Human Granulocyte macrophage Colony Stimulating Factor (GM-CSF) on chemotherapy-induced Myelosuppression in Patients with Sarcoma.** *Proceedings American Society of Clinical Oncology, #1254, vol 8, pp 322, 1989.* Authors: Vadhan-Raj S., Fenoglio C., Chawla S.P., Broxmeyer H. E., Gutterman J. U. and Benjamin R. S.
72. **Primary Chemotherapy of Osteosarcoma of the Extremities with systemic Adriamycin and Intra Arterial Cisplatinum.** *Proceedings American Society of Clinical Oncology, vol 8, #1251, pp 322, 1989.* Authors: Benjamin R. S., Raymond A. K., Carrasco C. H., Chawla S.P., Armen T., Ayala A. G. and Murray J.
73. **Recovery of Sperm Production after chemotherapy with Adriamycin and Cisplatinum.** *IV International Congress of Andrology, 1989.* Authors: Meistrich M. L., Chawla S.P. and DaCunha M. F.
74. **Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi-disciplinary Approach.** *Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.* Authors: Geopfert H., Spires J. R., Raymond A. K. and Chawla S.P.: Osteosarcoma of the Head and Neck. 32nd Annual Clinical Conference and 21st Annual Special Pathology Program.
75. **Cisplatin and Adriamycin as therapy for malignant fibrous histiocytoma of bone.** 32nd Annual Clinical Conference and 21st Annual Special Pathology Program. Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi-disciplinary Approach. *Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.* Authors: Chawla S.P., Benjamin R. S.,

Raymond A. K., Ayala A. G. and Murray J.

76. **Telangiectatic Osteosarcoma: Response to Chemotherapy and Limb Salvage.** 32nd Annual Clinical Conference and 21st Annual Special Pathology Program. Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi-disciplinary Approach. *Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.* Authors: Chawla S.P., Raymond A. K., Carrasco C. H., Ayala A. G., Murray J. and Benjamin R. S.
77. **Evaluation of a Triple Drug Regimen containing Cisplatin (C), Vinblastine and DTIC in patients with Metastatic melanoma.** *Proceedings of American Society of Clinical Oncology. Vol. 7, pp 250, #968, 1988.* Authors: Legha S., Ring S., Plager C., Papadopoulos N. E. J., Chawla S.P. and Benjamin R. S.
78. **A Randomized study of Carboplatin vs. Continuous Infusion of 5-Fluorouracil in Refractory Epithelial Ovarian Cancer.** *Proceedings of American Society of Clinical Oncology. Vol. 7, pp 148, # 572, 1988.* Authors: Chawla S.P., Gershenson D., Freedman R. S., Raber M., Gorski C., Kavanagh J., Smaldone L. and Wharton J. T.
79. **Chemotherapy of the Osteosarcoma of the Pelvis.** *Proceedings of American Association for Cancer Research #885, pp 223, vol. 29, 1988.* Authors: Paredes J., Chawla S.P., Raymond A. K., Carrasco C. H., Romsdahl N. M., Richli T. A. and Benjamin R. S.
80. **Pulmonary Toxicity and Limited Activity of Trimetrexate in Recurrent Carcinoma of Uterine Cervix.** *Proceedings of American Association for Cancer Research #823, pp 207, vol 29, 1988.* Authors: Chawla S.P., Kavanagh J. J., Freedman R. S., Raber M., Gershenson D., Edwards C. and Wharton T. J.
81. **Osteosarcoma Chemotherapy Effect: A Prognostic Factor.** *Sem Diag Path 4:212-236, 1987.* Authors: Raymond A. K., Chawla S.P., Carrasco C. H., Ayala A. G., Fanning C. V., Grive B., Armen T., Plager C., Papadopoulos N. E. J., Edeiken J., Wallace S., Jaffe N., Murray J. A., and Benjamin R. S.
82. **Aberrant expression on N-MYC and C-K-RAS as well as overall expression of C-SIS in fresh uncultured human melanoma/sarcoma.** *American Association of Cancer Research 28:20, 1987.* Authors: Shin D. M., Gupta V., Chawla S.P., Donner L., Gutterman J. and Blick M.
83. **Sequential use of vincristine (V), DTIC (D) and hydroxyurea (H) in advanced malignant melanoma.** *American Society of Clinical Oncology 6:129, 1987.* Authors: Papadopoulos N. E. J., Ring S., Plager C., Legha S., Chawla S.P., and Benjamin R. S.
84. **Evaluation of intravenous (IV) N-acetylcysteine (NAC) as an un-protector against Ifosfamide (IFF) toxicity in patients with advanced sarcomas.** *American Society of Clinical Oncology 6:129, 1987.* Authors: Legha S., Fitz K., Papadopoulos N. E. J., Chawla S.P., Plager C. and Benjamin R. S.
85. **Arteriographic prediction of tumor necrosis after primary treatment of osteosarcoma in adults.** *American Society of Clinical Oncology 6:129, 1987.* Authors: Carrasco C. H., Chawla S.P., Benjamin R. S., Raymond A. K., Ayala A. G., Murray J. and Wallace S.

86. **Ifosfamide (IFF) therapy for progressive pretreated metastatic sarcoma via compassionate IND.** *American Society of Clinical Oncology* 6:128, 1987. Authors: Plager C., Papadopoulos N. E. J., Chawla S.P., Sandberg S., Legha S. and Benjamin R. S.
87. **Preoperative Intra-arterial Cisplatin and Limb Salvage Surgery for Patients with High Grade Osteosarcoma of the Extremities.** *5th International Conference of the Adjuvant Therapy of Cancer. Tucson, Arizona, March, 1987.* Authors: Chawla S.P., Benjamin R. S., Jaffe N., Carrasco C. H., Raymond A. K., Ayala A., Wallace S., Armen T., Papadopoulos N. E. J., Plager C. and Murray J.
88. **Adjuvant Immunotherapy of MD Anderson Stage III-B Malignant Melanoma.** *5th International Conference of the Adjuvant therapy for Cancer. Tucson, Arizona, March 11-14, 1987.* Authors: Plager C., Bowen J. M., Fenoglio C. J., Papadopoulos N. E. J., Murray J., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. P. and Hersh E. M.
89. **Angiographic evaluation of response to preoperative chemotherapy in osteosarcoma.** *72nd Scientific Assembly of the Radiological Society of north America, 1986.* Authors: Carrasco C. H., Charnasangavej C., Richli W., Wallace S., Chawla S.P., Raymond A. K., Murray J. and Benjamin R. S.
90. **Role of chemotherapy in potential cure and limb salvage of high grade osteosarcoma of extremity.** *Indian Society of Oncology, 2nd Biennial Conference. Feb. 9-14, 1986, pp 165, 1986.* Authors: Chawla S.P., Benjamin R. S., Raymond A. K., Carrasco C. H., Wallace S., Murray J. and Ayala A.
91. **Clinical efficacy of Roferon-A in metastatic melanoma: A comparison to two dose schedules.** *American Society of Clinical Oncology* 4:228, 1986. Authors: Legha S., Pickett S., Plager C., Papadopoulos N. E. J., Chawla S.P., Itri L. and Benjamin R. S.
92. **Primary chemotherapy of patients with osteosarcoma of an extremity.** *American Society of Clinical Oncology* 4:139, 1986. Authors: Benjamin R.S., Chawla S.P., Carrasco C. H., Raymond A. K., Wallace S., Murray J., Ayala A. and Romsdahl M.
93. **Osteosarcoma, preoperative chemotherapy: histological evaluation.** *American Society of Clinical Oncology* 4:138, 1986. Authors: Raymond A. K., Benjamin R. S., Carrasco C. H., Ayala A., Chawla S.P., Wallace S. and Murray J.
94. **Malignant fibrous histiocytoma of the head and neck.** *American Society of Clinical Oncology* 4:138, 1986. Authors: Kramer A., Fayssoux F., Atkinson E. N., Chawla S.P., Byers R., Goepfert H., Dimery I. and Hong W. K.,
95. **Adjuvant Immunotherapy with Newcastle disease virus oncolysate of MD Anderson state III-B malignant melanoma.** *American Society of Clinical Oncology* 4:138, 1986. Authors: Plager C., Bowen J. M., Fenoglio C., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. D. and Hersh E. M.
96. **High dose intravenous cytoxan, carmustine, etoposide and autologous bone marrow transplant for advanced refractory small round cell sarcomas in adults.** *American Society of Clinical Oncology. 4:137, 1986.* Authors: Papadopoulos N. E. J., Armen T., Chawla, S.P., Horwitz L., Spitzer G., Dicke K., Plager C. and Benjamin R. S.
97. **Decreased cardiotoxicity of 96-hour continuous infusion adriamycin compared with Epirubicin.** *American Society of Clinical Oncology* 4:44, 1986. Authors: Chawla S.P.,

Benjamin R. S., Hortobagyi G. N., Ajani J. A. and Body G. P.

98. **Curative and limb-saving role of intra-arterial cis-platinum and systemic adriamycin in osteosarcoma.** *American Association for cancer Research. 27:182, 1986.* Authors: Chawla S.P., Benjamin R. S., Ayala A. G., Raymond A. J., Armen T., Carrasco C. H., Wallace S., Papadopoulos N. E. J., Plager C., Romsdahl M. M., Richli W. R. and Murray J.
99. **The cardiotoxicity of chemotherapeutic agents: evaluation by endomyocardial biopsy and nuclear Angiographic ejection fraction.** *14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.* Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H. and Mackay B.
100. **Correlation of ejection fractions and biopsy grades in patients receiving adriamycin.** *14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.* Authors: Ewer M. S., Chawla S.P., Carrasco C. H., Mackay B., Ali M. K., Haynie III T. P. and Benjamin R. S.
101. **Prognostically directed preoperative and postoperative chemotherapy and limb salvage surgery of high grade osteosarcoma.** *14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.* Authors: Chawla S.P., Benjamin R. S., Carrasco C. H., Raymond A. G., Papadopoulos N. E. J., Plager C. and Murray J. A.
102. **High rates of complete remission, limb salvage and prolonged survival in telangiectatic osteosarcoma after preoperative chemotherapy with intra-arterial cisplatinium and systemic adriamycin.** *American Society of Clinical Oncology 4:152, 1985.* Authors: Chawla S.P., Raymond A. K., Carrasco C. H., Papadopoulos N. E. J., Plager C., Romsdahl N. M., Ayala A. G., Wallace S., Murray J. A., Bodey G. P. and Benjamin R. S.
103. **High Dose intravenous melphalan, carmustine, etoposide and bone marrow transplant for advanced refractory malignancy.** *American Society of Clinical Oncology 4:151, 1985.* Authors: Papadopoulos N. E. J., Fayssoux R., Vellekoop L., Chawla S.P., Plager C., Spitzer G. and Benjamin R. S.
104. **Adjuvant immunotherapy with Newcastle disease virus oncolysate of MD Anderson state III-B malignant melanoma.** *American Society of Clinical Oncology 4:151, 1985.* Authors: Plager C., Bowen J. M., Fenoglio C., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S. and Hersh E. M.
105. **A comparison of resting and exercise ejection.** *American Society of Clinical Oncology 4:150, 1985.* Authors: Ewer M. S., Ali M. K., Chawla S.P., Carrasco C. H., Lamki L., Mackay B., Balakrishnan P. V., Johnston D. A. and Benjamin R. S.
106. **Phase II study of bisantrene in advanced malignant melanoma.** *American Association of Cancer Research. 26:174, 1985.* Authors: Papadopoulos N. E. J., Tenney D. M., Chawla S.P., Plager C. and Benjamin R. S.
107. **Response to preoperative chemotherapy of osteosarcoma improves disease-free survival and the chances of limb salvage.** *American Association for Cancer Research. 26:174, 1985.* Authors: Benjamin R. S., Chawla S.P., Murray J. A., Carrasco C. H., Raymond A. K., Ayala A., Wallace S., Romsdahl M. M., Plager C. and Papadopoulos N.

E. J.

108. **Sperm production following chemotherapy for sarcomas.** *American Association for Cancer Research. 26:170, 1985.* Authors: Meistrich M. L., deCunha M. F., Chawla S.P., Plager C., Papadopoulos N. E. J. and Benjamin R. S.
109. **Chemotherapy of primary osteosarcoma - A study of prognostic factors.** *4th International Conference of the Adjuvant Therapy of Cancer. Tucson, Arizona, March 21-24, 1984.* Authors: Benjamin R. S., Chawla S.P., Murray J. A., Wallace S., Carrasco C. H., Ayala A., Raymond A. K., Romsdahl M., Plager C. and Papadopoulos N. E. J.
110. **Adjuvant chemotherapy of primary malignant fibrous histiocytoma (MFH) of bone.** *4th International Conference of Adjuvant Therapy of Cancer. Tucson, Arizona, March 21-24, 1984.* Authors: Chawla S.P., Benjamin R. S., Ayala A. G., Evans H., Papadopoulos N. E. J., Plager C., Jaffe N. and Murray J. A.
111. **Phase II study of Bisantrene in advanced sarcoma.** *American Society of Clinical Oncology 3:263, 1984.* Authors: Papadopoulos N. E. J., Tenney D. M., Benjamin R. S., Plager C., Chawla S.P. and Bodey G. P.
112. **Detorubicin - an active anthracycline in metastatic melanoma.** *American Society of Clinical Oncology 3:263, 1984.* Authors: Chawla S.P., Benjamin R. S., Legha S., Plager C., Papadopoulos N. E. J., Ewer M. S., Mackay B., Bodey G. P. and Wang A.
113. **A review of epithelioid sarcoma.** *American Society of Clinical Oncology 3: 262, 1984.* Authors: Plager C., Papadopoulos N. E. J., Chawla S.P., Ayala A. G., Yap B. S., Romsdahl M. M., Martin R. G., Cangir A., Lindberg R. D., and Benjamin R. S.
114. **Evaluation of Mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy.** *American Society of Clinical Oncology 3:40, 1984.* Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., Haynie III T. P., Yap H. Y., Blumenschein G. R., Holmes F., Ali M. K. and Bodey G. P.
115. **Clinical pharmacology of homoharringtonine (HHT).** *ASCO: 38, 1984.* Authors: Savaraj N., Lu K., Dimery I., Feun L., Burgess M. A. Guo Z., Chawla S.P. and Loo T. L.
116. **Phase II study of combination of 4-9 acridinylomino methanesulfon-M-anisidide (AMSA) and cis-platinum diamino-dichloride cisplatin (CDDP) in the treatment of adult acute leukemia (ALL).** *American Society of Clinical Oncology 2:172, 1983.* Authors: Chawla S.P., McCredie K. B., Keating M. J., Estey E., Walters R. S., Bodey G. P., and Freireich E. J.
117. **Cardiac toxicity of high cumulative dose adriamycin by rapid or 24-96 hour continuous infusion.** *American Society of Clinical Oncology 2:40, 1983.* Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Wallace S. R., Mackay B., Carrasco C. H., Legha S. S., Mann G., Hortobagyi G. N., Valdivieso M., Ali M. K., and Haynie T. P.
118. **Primary malignant fibrous histiocytoma of bone - A chemotherapy responsive tumor.** *American Association for Cancer Research 24:144, 1983.* Authors: Benjamin R. S., Chawla S.P., Plager P., Papadopoulos N. E., Yap B., Ayala A. G., Wallace S. R., Saunders P. P. And Murray JA.
119. **Monitoring of adriamycin cardiotoxicity beyond the conventional limits of 500 mg/**

m2. *American Association of Cancer Research 24:134, 1983.* Authors: Chawla S.P., Mann G. Benjamin R. S., Legha S. S., Mackay B., Ewer M. S., Ali M. K., Carrasco C. H., Hortobagyi G. N., Wallace S. R., Valdivieso M., Kim E. E., and Haynie T. P.

Poster Presentations

- 1. Randomized Phase III Trial of Trabectedin versus Doxorubicin-based Chemotherapy as First Line Therapy in Translocation-Related Sarcomas.** *ASCO Annual Meeting, Chicago, May 31-June 4, 2013.* Andrew Hendifar, Sant P. Chawla, Michael Gordon Leahy, Antoine Italiano, Shreyaskumar Patel, Peter Hohenberger, Armando Santoro, Arthur P. Staddon, Nicolas Penel, Sophie Piperno-Neumann, George D. Demetri, Larry Hayward, Jeff White, Launce G. Gouw, Bernardo Miguel-Lillo, Pilar Lardelli, Arturo Soto-Matos, Antonio Nieto, Jean-Yves Blay.
- 2. 14 Day Continuous Infusion High Dose Ifosfamide in Adolescent and Adult Sarcoma Patients, an Updated Analysis.** *CTOS Annual Meeting, Prague, Czech Republic, November 14-17, 2012.* Harsha Rajashekaraiah, Andrew Hendifar, Victoria Chua, Doris Quon, Lita Fernandez, Kristen Ganjoo, Kamallesh Sankhala, Vivek Narasimhan, David Shin, Monish Sodhi, Alison Bonk, Pritesh Chaudhari, and Sant Chawla.
- 3. Lo Dose Gemcitabine, Doxorubicin, and Docetaxel Combination in Patients with Advanced, Unresectable and/or Metastatic Sarcoma Who had Failed Prior Chemotherapy, an Updated Analysis.** *CTOS Annual Meeting, Prague, Czech Republic, November 14-17, 2012.* Vivek Narasimhan, Andrew Hendifar, Victoria Chua, Doris Quon, Lita Fernandez, Harsha Rajashekaraiah, David Shin, Alison Bonk, Monish Sodhi, Pritesh Chaudhari and Sant Chawla.
- 4. INNO-206 is an active drug for relapsed advanced soft tissue sarcoma.** *37th ESMO Congress, Vienna, Austria, September 28 – October 2, 2012.* S. Chawla, V.S. Chua, A. Hendifar, D. Quon, S. Nagre, K.N. Ganjoo, K. Sankhala, Y. Lavinski, S. Wieland, D. Levitt.
- 5. 14 Day Continuous Infusion High-Dose Ifosfamide in Adolescent and Adult Sarcoma Patients.** *ASCO Annual Meeting, Oct, 2011.* Andrew Hendifar, Shelly Chawla, Sandeep Nagre, Vicky Chua, Lita Fernandez, Bartosz Chmielowski, James Hu, and Sant Chawla.
- 6. A Phase 2 Dose Expansion of TH-302 in combination with Doxorubicin in Advanced soft Tissue Sarcoma.** *ASCO Annual Meeting, June 3-7, 2011.* Chawla S.P. et al.